Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Apremilast in Japanese Patients With Palmoplantar Pustulosis
jRCT2031210662Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Palmoplantar Pustular Psoriasis (PPPP) comparing Apremilast with Placebo then Apremilast (2 arms). Primary endpoint: PPPASI-50 response at Week 16. Started Mar 2022; status: completed.
02
Drugs
apremilast
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on jRCT2031210662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210662.